Petosemtamab

派森妥单抗

Report date: 2026/04/03 20:03:44

Base Information

Drug NamePetosemtamab
Drug Alias NameMCLA-158
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsLeucine-rich repeat-containing G-protein coupled receptor 5 antagonistsWnt signalling pathway modulators
TargetsEpidermal growth factor receptor erbB1Leucine-rich repeat-containing G-protein coupled receptor 5
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerus Nv
China Registration ClassN/A

Develop Information

Active CompaniesMerus Nv
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A